ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity
In this MEDtalk, Dimitrios Salgkamis, PhD student at Karolinska Institutet, presents preliminary findings from a genome-wide association study embedded in the PANTHER phase III trial, shared at ESMO Breast Cancer 2025. The analysis identified single-nucleotide polymorphisms associated with increased risk of neutropenia and leukopenia after the first chemotherapy cycle in high-risk early breast cancer patients, offering insights into potential biomarkers for treatment-related toxicity.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in